Doxylamine/Pyridoxine Exeltis 10 mg/10 mg gastro-resistant tablets Ireland - English - HPRA (Health Products Regulatory Authority)

doxylamine/pyridoxine exeltis 10 mg/10 mg gastro-resistant tablets

exeltis healthcare s.l. - doxylamine; pyridoxine hydrochloride - gastro-resistant tablet - 10/10 milligram(s) - doxylamine, combinations

Doxylamine/Pyridoxine Exeltis Healthcare 20mg/ 20mg modified-release tablets Ireland - English - HPRA (Health Products Regulatory Authority)

doxylamine/pyridoxine exeltis healthcare 20mg/ 20mg modified-release tablets

exeltis healthcare s.l. - doxylamine hydrogen succinate; pyridoxine hydrochloride - modified-release tablet - doxylamine, combinations

VITAFOL- cholecalciferol, pyridoxine hydrochloride, cyanocobalamin, and folic acid strip United States - English - NLM (National Library of Medicine)

vitafol- cholecalciferol, pyridoxine hydrochloride, cyanocobalamin, and folic acid strip

exeltis usa, inc. - cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8) - vitafol® strips is contraindicated in patients with hypersensitivity to any of its components or color additives. folic acid is contraindicated in patients with untreated and uncomplicated pernicious anemia, and in those with anaphylactic sensitivity to folic acid. cyanocobalamin is contraindicated in patients with sensitivity to cobalt or to cyanocobalamin (vitamin b12).

Xonvea 10 mg/10 mg gastro-resistant tablets Ireland - English - HPRA (Health Products Regulatory Authority)

xonvea 10 mg/10 mg gastro-resistant tablets

exeltis healthcare s.l. - doxylamine hydrogen succinate; pyridoxine hydrochloride - gastro-resistant tablet - doxylamine, combinations

Doxpirexel 20 mg/ 20 mg modified-release tablets Ireland - English - HPRA (Health Products Regulatory Authority)

doxpirexel 20 mg/ 20 mg modified-release tablets

exeltis healthcare s.l. - pyridoxine hydrochloride ; doxylamine hydrogen succinate - modified-release tablet - doxylamine, combinations

Xonvea MR 20 mg/20 mg modified-release tablets Ireland - English - HPRA (Health Products Regulatory Authority)

xonvea mr 20 mg/20 mg modified-release tablets

exeltis healthcare s.l. - doxylamine hydrogen succinate; pyridoxine hydrochloride - modified-release tablet - doxylamine, combinations

STROVITE ONE CAPLETS- vitamin a, calcium pantothenate, ascorbic acid, cholecalciferol, .alpha.-tocopherol succinate, d-, thiamin United States - English - NLM (National Library of Medicine)

strovite one caplets- vitamin a, calcium pantothenate, ascorbic acid, cholecalciferol, .alpha.-tocopherol succinate, d-, thiamin

exeltis usa, inc. - manganese (unii: 42z2k6zl8p) (manganese - unii:42z2k6zl8p), vitamin a (unii: 81g40h8b0t) (vitamin a - unii:81g40h8b0t), calcium pantothenate (unii: 568et80c3d) (pantothenic acid - unii:19f5hk2737, calcium cation - unii:2m83c4r6zb), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol succinate, d- (unii: lu4b53jyve) (.alpha.-tocopherol, d- - unii:n9pr3490h9), thiamine (unii: x66nso3n35) (thiamine - vitamin a 3000 [iu] - strovite ® one is indicated to provide nutritional supplementation to support optimum vitamin and mineral levels. strovite ® one is contraindicated in patients with hypersensitivity to any of its components. folic acid is contraindicated in patients with untreated and uncomplicated pernicious anemia, and in those with anaphylactic sensitivity to folic acid. cyanocobalamin is contraindicated in patients with sensitivity to cobalt or to cyanocobalamin (vitamin b12).

VITAFOL ULTRA- doconexent, niacinamide, .alpha.-tocopherol acetate, dl-, cholecalciferol, .beta.-carotene, ascorbic acid, thiami United States - English - NLM (National Library of Medicine)

vitafol ultra- doconexent, niacinamide, .alpha.-tocopherol acetate, dl-, cholecalciferol, .beta.-carotene, ascorbic acid, thiami

exeltis usa, inc. - doconexent (unii: zad9okh9jc) (doconexent - unii:zad9okh9jc), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), .alpha.-tocopherol acetate, dl- (unii: wr1wpi7ew8) (.alpha.-tocopherol, dl- - unii:7qwa1rio01), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), beta carotene (unii: 01yae03m7j) (beta carotene - unii:01yae03m7j), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), thiamine mononitrate (unii: 8k0i04919x) (thiamine ion - unii:4abt0j945j), r - doconexent 200 mg - vitafol ® ultra is contraindicated in patients with hypersensitivity to any of its components or color additives. folic acid is contraindicated in patients with untreated and uncomplicated pernicious anemia, and in those with anaphylactic sensitivity to folic acid. iron therapy is contraindicated in patients with hemochromatosis and patients with iron storage disease or the potential for iron storage disease due to chronic hemolytic anemia (e.g., inherited anomalies of hemoglobin structure or synthesis and/or red cell enzyme deficiencies, etc.), pyridoxine responsive anemia, or cirrhosis of the liver. cyanocobalamin is contraindicated in patients with sensitivity to cobalt or to cyanocobalamin (vitamin b12).

VITAFOL NANO- cholecalciferol, pyridoxine hydrochloride, folic acid, levomefolate calcium, cyanocobalamin, iron, and iodine tabl United States - English - NLM (National Library of Medicine)

vitafol nano- cholecalciferol, pyridoxine hydrochloride, folic acid, levomefolate calcium, cyanocobalamin, iron, and iodine tabl

exeltis usa, inc. - cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), levomefolate calcium (unii: a9r10k3f2f) (levomefolic acid - unii:8s95dh25xc), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), iron (unii: e1uol152h7) (iron - unii:e1uol152h7), iodine (unii: 9679tc07x4) (iodine - unii:9679tc07x4) - cholecalciferol 1000 [iu] - vitafol ® -nano is contraindicated in patients with hypersensitivity to any of its components or color additives. folic acid is contraindicated in patients with untreated and uncomplicated pernicious anemia, and in those with anaphylactic sensitivity to folic acid. iron therapy is contraindicated in patients with hemochromatosis and patients with iron storage disease or the potential for iron storage disease due to chronic hemolytic anemia (e.g., inherited anomalies of hemoglobin structure or synthesis and/or red cell enzyme deficiencies, etc.), pyridoxine responsive anemia, or cirrhosis of the liver. cyanocobalamin is contraindicated in patients with sensitivity to cobalt or to cyanocobalamin (vitamin b12).

VITAFOL OB CAPLET- vitamin a, ascorbic acid, vitamin d, .alpha.-tocopherol, thiamine mononitrate, riboflavin, niacin, pyridoxine United States - English - NLM (National Library of Medicine)

vitafol ob caplet- vitamin a, ascorbic acid, vitamin d, .alpha.-tocopherol, thiamine mononitrate, riboflavin, niacin, pyridoxine

exeltis usa, inc. - vitamin a (unii: 81g40h8b0t) (vitamin a - unii:81g40h8b0t), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), vitamin d (unii: 9vu1ki44gp) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol (unii: h4n855pnz1) (.alpha.-tocopherol - unii:h4n855pnz1), thiamine mononitrate (unii: 8k0i04919x) (thiamine ion - unii:4abt0j945j), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), niacin (unii: 2679mf687a) (niacin - unii:2679mf687a), pyridoxine hydrochloride (unii: 68y4cf58bv) - vitamin a 2700 [iu] - vitafol ® -ob is indicated to provide vitamin, mineral, supplementation prior to conception, throughout pregnancy, and during the postnatal period for the lactating and non-lactating mother.* vitafol ® -ob is contraindicated in patients with hypersensitivity to any of its components or color additives. folic acid is contraindicated in patients with untreated and uncomplicated pernicious anemia, and in those with anaphylactic sensitivity to folic acid. iron therapy is contraindicated in patients with hemochromatosis and patients with iron storage disease or the potential for iron storage disease due to chronic hemolytic anemia (e.g., inherited anomalies of hemoglobin structure or synthesis and/or red cell enzyme deficiencies, etc.), pyridoxine responsive anemia, or cirrhosis of the liver. cyanocobalamin is contraindicated in patients with sensitivity to cobalt or to cyanocobalamin (vitamin b-12).